DKK1 Human Sf9

DKK1 is a secreted protein characterized by two conserved cysteine-rich domains separated by a linker region and an N-terminal signal peptide . The protein inhibits the canonical Wnt pathway by binding to low-density lipoprotein receptors (LRP)-5 and 6 with high affinity, thereby decreasing β-catenin protein stability . This inhibition is essential for regulating embryonic development and maintaining cellular homeostasis.

DKK1 has been implicated in various diseases and conditions:

• Multiple Myeloma: High levels of DKK1 in bone marrow plasma and peripheral blood are associated with osteolytic bone lesions in patients with multiple myeloma .
• Cancer: DKK1 expression is reduced in human colon tumors, suggesting its role as a tumor suppressor gene . The Wnt/β-catenin pathway is downregulated by DKK1, a mechanism that is often missing in colon cancer.
• Neurodegenerative Diseases: Induction of DKK1 contributes to the pathological cascade triggered by beta-amyloid and is significantly involved in the development of tau phosphorylation .

Recombinant DKK1, particularly the human recombinant form produced in Sf9 cells, is widely used in research to study its biological functions and therapeutic potential. The recombinant protein is typically produced in Baculovirus-infected Sf9 cells and purified using chromatographic techniques . It is available in various formulations and concentrations, making it suitable for a range of experimental applications.

The recombinant DKK1 protein is usually stored at 4°C for short-term use and at -20°C for long-term storage. It is recommended to add a carrier protein to prevent multiple freeze-thaw cycles, which can degrade the protein .